Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 7/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | QPCT | Q16769 | 1/20 | 0.30 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411369 | 1.00 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1TACR1CSF1R | |
| SCHEMBL4551750 | 1.00 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1TACR1CSF1R | |
| SCHEMBL3411368 | 1.00 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1TACR1CSF1R | |
| SCHEMBL3413240 | 0.88 | SLC5A2 (0.34) | SLC5A2SLC5A1SLC29A1 | |
| SCHEMBL4412796 | 0.88 | SLC5A2 (0.34) | SLC5A2SLC5A1SLC29A1 | |
| SCHEMBL3409047 | 0.88 | SLC5A2 (0.34) | SLC5A2SLC5A1SLC29A1 | |
| SCHEMBL3409039 | 0.88 | SLC5A2 (0.34) | SLC5A2SLC5A1SLC29A1 | |
| SCHEMBL4420233 | 0.87 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1CSF1R | |
| SCHEMBL3410151 | 0.87 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1CSF1R | |
| SCHEMBL4420237 | 0.87 | SLC5A2 (0.35) | SLC5A2SLC5A1SLC29A1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1679966-A4 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | claimed |
| EP-1679966-A2 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | claimed |
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | claimed |
| WO-2005012242-A2 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | GANAB, GCG, GANC | SLC5A2 18/4885SLC5A1 19/4885SLC29A1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.